Products You May Like
TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) — Medexus Prescription drugs Inc. (the “Firm” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)introduced right this moment that it’s initiating speedy availability of Triamcinolone Hexacetonide Injectable Suspension, USP (20 mg/ml) (TH) in the US through the U.S. Meals and Drug Administration’s (FDA) CDER Drug Scarcity program. Extra details about the FDA’s Drug Scarcity program is out there at: FDA Drug Shortages.
TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic remedy of subacute and persistent inflammatory joint ailments, together with: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis.
To handle the continued scarcity of TH in the US, Medexus is coordinating with Ethypharm, its licensing accomplice, to generate the info wanted to assist an Abbreviated New Drug Software (ANDA) submitting in an expedited timeframe.
About Medexus
Medexus is a number one progressive and uncommon illness firm with a powerful North American business platform. From a basis of confirmed finest at school merchandise we’re constructing a extremely differentiated firm with a portfolio of progressive and excessive worth orphan and uncommon illness merchandise that may underpin our progress for the subsequent decade. The Firm’s imaginative and prescient is to supply one of the best healthcare merchandise to healthcare professionals and sufferers, via our core values of High quality, Innovation, Buyer Service and Teamwork. Medexus Prescription drugs is targeted on the therapeutic areas of auto-immune illness, hematology, and allergy. The Firm’s main merchandise are: Rasuvo™ and Metoject®, a novel formulation of methotrexate (auto-pen and pre-filled syringe) designed to deal with rheumatoid arthritis and different auto-immune ailments; IXINITY®, an intravenous recombinant issue IX therapeutic to be used in sufferers 12 years of age or older with Hemophilia B – a hereditary bleeding dysfunction characterised by a deficiency of clotting issue IX within the blood, which is important to manage bleeding; and Rupall®, an progressive prescription allergy treatment with a novel mode of motion.
For extra data, please contact:
Ken d’Entremont, Chief Govt Officer
Medexus Prescription drugs Inc.
Tel.: 905-676-0003
E-mail: ken.dentremont@medexus.com
Roland Boivin, Chief Monetary Officer
Medexus Prescription drugs Inc.
Tel.: 514-344-8765
E-mail: roland.boivin@medexus.com
Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Electronic mail: mdp@crescendo-ir.com
Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: tina@adcap.ca
Ahead trying and different cautionary statements
Sure statements made on this press launch comprise forward-looking data throughout the which means of relevant securities legal guidelines (“forward-looking statements”). The phrases “anticipates”, “believes”, “expects”, “will”, “plans” and comparable expressions are sometimes supposed to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Particular forward-looking statements contained on this information launch embrace, however aren’t restricted to, statements with respect to the speedy availability of TH in the US and the Firm’s skill to generate the info wanted to assist an ANDA submitting in an expedited timeframe. These statements are primarily based on components or assumptions that have been utilized in drawing a conclusion or making a forecast or projection, together with assumptions primarily based on historic tendencies, present situations and anticipated future developments.
Since forward-looking statements relate to future occasions and situations, by their very nature they require making assumptions and contain inherent dangers and uncertainties. The Firm cautions that though it’s believed that the assumptions are affordable within the circumstances, these dangers and uncertainties give rise to the chance that precise outcomes could differ materially from the expectations set out within the forward-looking statements. Materials danger components embrace these set out within the Firm’s supplies filed with the Canadian securities regulatory authorities every so often, together with the Firm’s most up-to-date annual data kind and administration’s dialogue and evaluation. Given these dangers, undue reliance shouldn’t be positioned on these forward-looking statements, which apply solely as of the date hereof. Aside from as particularly required by regulation, the Firm undertakes no obligation to replace any forward-looking statements to mirror new data, subsequent or in any other case.
Neither the TSX Enterprise Trade nor its Regulation Companies Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Trade) accepts accountability for the adequacy or accuracy of this launch.
